
|Videos|May 28, 2020
A 69-Year-Old Woman With Follicular Lymphoma
Author(s)Ajay K. Gopal, MD
Ajay K. Gopal, MD, discusses the rationale for treating a 69-year-old woman with high-risk follicular lymphoma with a PI3-kinase inhibitor in the third-line setting.
Advertisement
Case:A 69-Year-Old Woman With Follicular Lymphoma
Initial Presentation
- A 69-year-old woman complains of a 5-month history of fatigue, decreased appetite and a 10-bs. weight loss
- PMH: unremarkable
- PE: right axillary and bilateral cervical lymph nodes palpated ~ 3 cm; spleen palpable 4 cm below costal margin
Clinical Work-up
- Labs: ANC 1.6 x 109/L, WBC 11.8 x 109/L, 40% lymphocytes, Hb 8.9 g/dL, plt 98 x 109/L, LDH 308 U/L, B2M 3.7 µg/mL; HBV negative
- Excisional biopsy of the lymph node on IHC showed CD 20+, CD 10+, BCL2+; follicular lymphoma grade 2
- Bone marrow biopsy showed paratrabecular lymphoid aggregates, 45% involvement
- Molecular genetics: t(14;18) (q32;q21)
- PET/CT showed enlargement of right axillary lymph nodes (3.1 cm, 3.2 cm), diffusely enlarged nodes in the retroperitoneal and lumbar lymph nodes
- Ann Arbor Stage IV; ECOG 1
Treatment
- She was treated with R-CHOP for 6 cycles with rituximab maintenance; achieved partial response
- 5 months later she complained of increasing fatigue
- Repeat PET/CT revealed progression of disease
- She was started on bendamustine + obinutuzumab for 6 cycles and continued maintenance obinutuzumab
- Repeat lymph node biopsy remained grade 1-2 follicular lymphoma
- 9 months later she complained of chills and low-grade fever
- She was started on idelalisib 150 mg PO BID
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5






































